Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial

[1]  C. Hassager,et al.  Management of acute atrial fibrillation in the intensive care unit: An international survey , 2021, Acta anaesthesiologica Scandinavica.

[2]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[3]  J. D. Young,et al.  Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review , 2020, BMJ Open.

[4]  M. Balík,et al.  Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study , 2019, BMJ Open.

[5]  M. Balík.  New-onset atrial fibrillation in critically ill patients - Implications for rhythm rather than rate control therapy? , 2018, International journal of cardiology.

[6]  Seung‐Jung Park,et al.  Which antiarrhythmic drug to choose after electrical cardioversion: A study on non-valvular atrial fibrillation patients , 2018, PLoS ONE.

[7]  J. Healey,et al.  Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis , 2018, JAMA.

[8]  G. Tavazzi,et al.  Propafenone for supraventricular arrhythmias in septic shock—Comparison to amiodarone and metoprolol , 2017, Journal of critical care.

[9]  O. Olivieri,et al.  Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs , 2017, Internal and Emergency Medicine.

[10]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[11]  F. Taccone,et al.  Beta-blockers in septic shock to optimize hemodynamics? No , 2016, Intensive Care Medicine.

[12]  P. Lercher,et al.  Propafenone shows class Ic and class II antiarrhythmic effects. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[13]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[14]  J. Piccini,et al.  Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. , 2015, The American journal of cardiology.

[15]  O. Cremer,et al.  Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review , 2014, Critical Care.

[16]  M. Singer,et al.  Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. , 2013, JAMA.

[17]  J. Korinek,et al.  Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock , 2012, Wiener klinische Wochenschrift.

[18]  A. Tveit,et al.  The Predictive Value of Transthoracic Echocardiographic Variables for Sinus Rhythm Maintenance after Electrical Cardioversion of Atrial Fibrillation , 2007, Cardiology.

[19]  W. Manning,et al.  Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. , 1994, Journal of the American College of Cardiology.